Therapy outcome related to adalimumab trough levels in pediatric patients with inflammatory bowel disease

CONCLUSION: Higher trough levels in the first 3 months of adalimumab treatment are associated with lower rates of discontinuation due to loss of response during the first year.PMID:34546843 | DOI:10.1080/00365521.2021.1977843

Source: Scandinavian Journal of Gastroenterology - September 21, 2021 Category: Gastroenterology Authors: Johanna Lehtom äki Anne Nikkonen Laura Merras-Salmio Pauliina Hiltunen Kaija-Leena Kolho Source Type: research